Protalix BioTherapeutics, Inc.

The business, in plain English

Protalix BioTherapeutics, Inc. booked $52.7M of revenue in FY2025 in the Healthcare sector and kept 48.8% of it as gross profit — a solid-margin business by that measure. After every other cost, −12.5% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $388000 (FY2009) to $52.7M (FY2025) — about 35.9% a year compounded over 16 years.

It earned −13.0% on invested capital in the latest filed year, FY2025. Across the full 3-year measurable filed record, median ROIC was 11.8%. Over the v3 recent window (3 measurable filed years), median ROIC was 11.8%. The Returns on Capital filter above scores it 41/100.

PLX's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Pricing Power is the strongest of the five filters (67/100) and Returns on Capital the weakest (41/100), which is how PLX lands at 52/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.